Known targets — ChEMBL curated mechanism
PRKAA1PRKAA2PRKAB1PRKAB2PRKAG1PRKAG2PRKAG3
The experimentally established mechanism targets of Acadesine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | FBP1 | P09467 | 1/20 | 0.69 |
| ▸ | ATIC | P31939 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | THPO | P40225 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acadesine SCHEMBL219336 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL7141001 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL28745421 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL2619704 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL10017743 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL6113798 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL5053863 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL14520658 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL2631614 | 1.00 | KDM4E (1.00) | KDM4ETP53TDP1MAPTSMN1; SMN2 | |
| Acadesine SCHEMBL8722270 | 0.95 | KDM4E (0.91) | KDM4ETP53TDP1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041767-A1 | Mitochondria-Enriched Extracellular Vesicles | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2024-02-08 | — | — | US | claimed |
| EP-0994952-A1 | PLANT ATP-PHOSPHORIBOSYL TRANSFERASE AND DNA CODING THEREFOR | Novartis AG (CH) | 2000-04-26 | — | — | EP | claimed |
| WO-1999005286-A1 | PLANT ATP-PHOSPHORIBOSYL TRANSFERASE AND DNA CODING THEREFOR | NOVARTIS AG (CH) | 1999-02-04 | — | — | WO | claimed |
| EP-3833359-B1 | AMP-ACTIVATED PROTEIN KINASE ACTIVATING COMPOUNDS AND USES THEREOF | SKYLARK BIOSCIENCE LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2024-02-15 | — | — | US | disclosed |
| US-11834469-B2 | AMP-activated protein kinase activating compounds and uses thereof | SKYLARK BIOSCIENCE LLC (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11779590-B2 | AMP-activated protein kinase activating compounds and uses thereof | SKYLARK BIOSCIENCE LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230279035-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | MITOPOWER, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| WO-2002068395-A1 | HIV INHIBITING N-AMINOIMIDAZOLE DERIVATIVES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-09-06 | — | — | WO | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0994952-A1 | PLANT ATP-PHOSPHORIBOSYL TRANSFERASE AND DNA CODING THEREFOR | Novartis AG (CH) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999005286-A1 | PLANT ATP-PHOSPHORIBOSYL TRANSFERASE AND DNA CODING THEREFOR | NOVARTIS AG (CH) | 1999-02-04 | — | — | WO | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050459-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | KDM4E 3520/4885TP53 1299/4885TDP1 483/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | KDM4E 3059/4885TP53 1728/4885TDP1 597/4885 |
| US-20230279035-A1 | Novel Prodrugs Derived from Nicotinic Acid and Ribose | NME4, NADK, NAMPT | KDM4E 4098/4885TP53 1885/4885TDP1 394/4885 |
| US-11779590-B2 | AMP-activated protein kinase activating compounds and uses thereof | MYLK2, PRKAG1, PRKAG3 | KDM4E 2380/4885TP53 432/4885TDP1 221/4885 |
| US-11834469-B2 | AMP-activated protein kinase activating compounds and uses thereof | PRKAG1, PRKAG2, PRKAG3 | KDM4E 3603/4885TP53 898/4885TDP1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.